StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

BioXcel Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -9549.9%. For fiscal 2025 it was -10887.4%, against -2630.1% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-10887.4%−8257.2
FY2024Dec 31, 2024-2630.1%+10344.7
FY2023Dec 31, 2023-12974.9%+31227.0
FY2022Dec 31, 2022-44201.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-8084.1%+7905.1
Q1 FY2026Mar 31, 2026-6160.7%−1842.8
Q4 FY2025Dec 31, 2025-4900.4%−1933.5
Q3 FY2025Sep 30, 2025-31541.8%−25163.3
Q2 FY2025Jun 30, 2025-15989.2%−15237.4
Q1 FY2025Mar 31, 2025-4317.9%+285.4
Q4 FY2024Dec 31, 2024-2966.9%+2952.2
Q3 FY2024Sep 30, 2024-6378.5%+8426.8
Q2 FY2024Jun 30, 2024-751.7%+10958.3
Q1 FY2024Mar 31, 2024-4603.3%+21025.9
Q4 FY2023Dec 31, 2023-5919.1%+17109.4
Q3 FY2023Sep 30, 2023-14805.3%+15709.3
Q2 FY2023Jun 30, 2023-11710.1%–
Q1 FY2023Mar 31, 2023-25629.1%–
Q4 FY2022Dec 31, 2022-23028.6%–
Q3 FY2022Sep 30, 2022-30514.6%–

More BioXcel Therapeutics figures

See a number that looks wrong?